PHARMACOKINETICS OF 14C LABELED ANTIRETROVIRAL NUCLEOSIDE

14C标记的抗逆转录病毒核苷的药代动力学

• 批准号: 6116345
• 负责人: Che-Chung Tsai
• 金额: $ 8.67万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-05-01 至 2000-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6116345
• 关键词: AIDS; Mammalia; Primates; cardiovascular system; clinical research; clinical trials; drug adverse effect; immunology; infection; inflammation; lymphatic system; orphan disease /drug; urinary tract; virus; AIDS; Mammalia; Primates; cardiovascular system; clinical research; clinical trials; drug adverse effect; immunology; infection; inflammation; lymphatic system; orphan disease /drug; urinary tract; virus

A thorough understanding of the plasma and intracellular levels of antiretroviral drugs and their metabolites is essential in order to judge a compound's actual potential in humans. In a study to determine the intracellular half-life of the antiretroviral compounds GS-0397 and GS-1278, both were labeled with 14C and injected subcutaneously into macaques. Blood and lymph node samples were collected at various time intervals and the concentrations of the radioactive material in the plasma, blood cells, and lymph nodes were determined by quantitative methods.

对抗逆转录病毒药物及其代谢产物的血浆和细胞内水平的透彻理解对于判断化合物在人类中的实际潜力至关重要。 在一项研究中，确定抗逆转录病毒化合物的细胞内半衰期GS-0397和GS-1278，两者均标记为14C，并皮下注射为猕猴。 通过不同的时间间隔收集血液和淋巴结样品，并通过定量方法确定血浆，血细胞和淋巴结中放射性材料的浓度。